logo

For the Inventor, By the Inventor

Sean Michael Kerwin

Round Rock, TX, United States of America

Sean Michael Kerwin

LinkedIn

This inventor holds 16 USPTO granted patents, primarily in Antitumor Agents. Top assignees: The University of Texas System, Research Development Foundation, Ctrc Research Foundation. Active years: 1999-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sean Michael Kerwin. Retrieved from https://idiyas.com/inventor/sean-michael-kerwin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16

% Patents Active = 75.0

Average Co-Inventor Count = 3.3

ph-index = 8

Forward Citations = 441(Granted Patents)


Company Filing History:

goldMedal9 out of 5,649 
 
The University of Texas System
 patents
silverMedal4 out of 299 
 
Research Development Foundation
 patents
bronzeMedal1 out of 5 
 
Ctrc Research Foundation
 patents
4. 1 out of 1 
 
Ctrc Research Foundation Board of Regents
 patent
5. 1 out of 28 
 
Osteoscreen, Inc.
 patents
6. 1 out of 723 
 
Zymogenetics, Inc.
 patents
7. 3 out of 834,708 
Other
 patents
where one patent can have more than one assignee

Years Active: 1999-2007

Loading Chart...
Areas of Expertise:
Antitumor Agents
Telomerase Inhibition
Bone Deficit Treatments
DNA-Cleaving
Osteoblast Proliferation
G-Quadruplex Interaction
Ricin Inhibitors
Quinobenzoxazine Analogues
Topoisomerase II
Malignant Cell Proliferation
Benzothiazole
Compositions and Methods
16 patents (USPTO):Explore Patents
1. 7294643 - UK-1 analogues: methods of preparation and use (2007-11-13),
2. 6908948 - DNA-cleaving antitumor agents (2005-06-21),
3. 6720344 - Methods and compositions for stimulating osteoblast proliferation or treating malignant cell proliferation and methods for selecting osteoblast proliferation stimulants (2004-04-13),
4. 6689887 - Inhibition of human telomerase by a G-quadruplex-interaction compound (2004-02-10),
5. 6686345 - DNA-cleaving antitumor agents (2004-02-03),
6. 6649631 - Compositions and methods for treating bone deficit conditions (2003-11-18),
7. 6623930 - Inhibition of human telomerase by a G-quadruplex-interaction compound (2003-09-23),
8. 6593306 - Methods for modulation and inhibition of telomerase (2003-07-15),
9. 6562969 - Ricin inhibitors and methods for use thereof (2003-05-13),
10. 6528517 - Synthesis of quinobenzoxazine analogues with topoisomerase II and quadruplex interactions for use as antineoplastic agents (2003-03-04),
11. 6297284 - DNA-cleaving antitumor agents (2001-10-02),
12. 6177280 - Ricin inhibitors and methods for use thereof (2001-01-23),
13. 6156763 - Inhibition of human telomerase by a g-quadruplex-interaction compound (2000-12-05),
14. 6054442 - Methods and compositions for modulation and inhibition of telomerase in (2000-04-25),
15. 6004939 - Methods for modulation and inhibition of telomerase (1999-12-21),

Title: Sean Michael Kerwin: Pioneering Innovator in Cancer Research

Introduction:

Sean Michael Kerwin, a remarkable inventor based in Round Rock, TX, has made significant contributions to the world of innovation with his inventive mindset and dedication to excellence. His groundbreaking inventions are shaping the future of cancer research and treatment.

Latest Patents:

Among his 16 patents, Sean Michael Kerwin's latest patents stand out for their impact on the field of oncology. One of his inventions includes UK-1 analogues, which have shown promising results in targeting cancer cells selectively. Additionally, his DNA-cleaving antitumor agents have opened new possibilities for advanced cancer treatments.

Career Highlights:

Throughout his career, Sean Michael Kerwin has demonstrated a strong focus on advancing cancer research. His work at the University of Texas System and Research Development Foundation has led to numerous breakthroughs in the field of oncology, setting new standards for innovative cancer treatments.

Collaborations:

Sean Michael Kerwin has worked closely with esteemed colleagues such as Laurence H Hurley and Miguel Salazar. Together, they have combined their expertise to push the boundaries of cancer research and develop novel solutions for combating this complex disease.

Conclusion:

Sean Michael Kerwin's relentless pursuit of excellence in innovation has established him as a visionary pioneer in the field of cancer research. His inventive spirit and collaborative efforts continue to drive towards creating transformative inventions that have the potential to revolutionize the landscape of oncology and benefit countless lives worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…